These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 8784662)

  • 41. A randomized, double-blind, and placebo-controlled trial of quetiapine augmentation of fluoxetine in major depressive disorder.
    Garakani A; Martinez JM; Marcus S; Weaver J; Rickels K; Fava M; Hirschowitz J
    Int Clin Psychopharmacol; 2008 Sep; 23(5):269-75. PubMed ID: 18703936
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study.
    Erzegovesi S; Guglielmo E; Siliprandi F; Bellodi L
    Eur Neuropsychopharmacol; 2005 Jan; 15(1):69-74. PubMed ID: 15572275
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Venlafaxine withdrawal symptoms.
    Benazzi F
    Can J Psychiatry; 1996 Sep; 41(7):487. PubMed ID: 8884044
    [No Abstract]   [Full Text] [Related]  

  • 44. Excessive weight gain after remission of depression in a schizophrenic patient treated with risperidone: case report.
    Theleritis CG; Papadimitriou GN; Papageorgiou CC; Dikeos DG; Masdrakis V; Kostoulas C; Psarros C; Soldatos CR
    BMC Psychiatry; 2006 Sep; 6():37. PubMed ID: 16953883
    [TBL] [Abstract][Full Text] [Related]  

  • 45. An integrated analysis of olanzapine/fluoxetine combination in clinical trials of treatment-resistant depression.
    Trivedi MH; Thase ME; Osuntokun O; Henley DB; Case M; Watson SB; Campbell GM; Corya SA
    J Clin Psychiatry; 2009 Mar; 70(3):387-96. PubMed ID: 19284928
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Therapeutic effects and tolerability of fluvoxamine treatment in adolescents with dysthymia.
    Rabe-Jablonska J
    J Child Adolesc Psychopharmacol; 2000; 10(1):9-18. PubMed ID: 10755577
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Risperidone as monotherapy for a patient with obsessive compulsive disorder comorbid with schizoaffective disorder: a case report.
    Chiou YJ; Lin PY; Lee Y
    Clin Neuropharmacol; 2015; 38(3):114-6. PubMed ID: 25970281
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Are study dropouts different from completers?
    Tedlow JR; Fava M; Uebelacker LA; Alpert JE; Nierenberg AA; Rosenbaum JF
    Biol Psychiatry; 1996 Oct; 40(7):668-70. PubMed ID: 8886303
    [No Abstract]   [Full Text] [Related]  

  • 49. L-Acetylcarnitine in dysthymic disorder in elderly patients: a double-blind, multicenter, controlled randomized study vs. fluoxetine.
    Bersani G; Meco G; Denaro A; Liberati D; Colletti C; Nicolai R; Bersani FS; Koverech A
    Eur Neuropsychopharmacol; 2013 Oct; 23(10):1219-25. PubMed ID: 23428336
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Olanzapine-fluoxetine combination for the treatment of bipolar depression.
    Citrome L
    Expert Opin Pharmacother; 2011 Dec; 12(17):2751-8. PubMed ID: 22035291
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Raynaud’s phenomenon in a patient with schizophrenia and obsessive-compulsive disorder: a case report.
    Korkmaz S; Işik U; Korkmaz H
    Turk Psikiyatri Derg; 2011; 22(2):132-3. PubMed ID: 21780344
    [No Abstract]   [Full Text] [Related]  

  • 52. [Potentialities of treating secondary dysthymia with painful dysfunction of temporomandibular joint].
    Gorozhankina EA; Markov BP; Mamedov FM
    Stomatologiia (Mosk); 2003; 82(5):44-7. PubMed ID: 14608350
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Three cases of paraphilias responsive to fluoxetine treatment.
    Perilstein RD; Lipper S; Friedman LJ
    J Clin Psychiatry; 1991 Apr; 52(4):169-70. PubMed ID: 2016251
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Sex- and age-related differences in major depressive disorder with comorbid anxiety treated with fluoxetine.
    Cassano P; Soares CN; Cohen LS; Lyster AK; Fava M
    Arch Womens Ment Health; 2004 Jul; 7(3):167-71. PubMed ID: 15241662
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Quetiapine add-on therapy improves the depressive behaviors and hippocampal neurogenesis in fluoxetine treatment resistant depressive rats.
    Wang Y; Chang T; Chen YC; Zhang RG; Wang HN; Wu WJ; Peng ZW; Tan QR
    Behav Brain Res; 2013 Sep; 253():206-11. PubMed ID: 23876404
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Risperidone, an atypical antipsychotic enhances the antidepressant-like effect of venlafaxine or fluoxetine: possible involvement of alpha-2 adrenergic receptors.
    Dhir A; Kulkarni SK
    Neurosci Lett; 2008 Nov; 445(1):83-8. PubMed ID: 18778754
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Use of fluoxetine in somatic delusional disorder].
    Quarantini Lde C; Rosário-Campos MC; Batista-Neves SC; Miranda-Scippa A; Sampaio AS
    Braz J Psychiatry; 2004 Jun; 26(2):138. PubMed ID: 15517068
    [No Abstract]   [Full Text] [Related]  

  • 58. Water, water, everywhere, nor any drop to drink: climate change delusion.
    Wolf J; Salo R
    Aust N Z J Psychiatry; 2008 Apr; 42(4):350. PubMed ID: 18330779
    [No Abstract]   [Full Text] [Related]  

  • 59. [Seizures crisis following sudden stop of fluoxetine].
    Epelde F; Plà R; Aguilar M
    Med Clin (Barc); 1999 Oct; 113(12):479. PubMed ID: 10570524
    [No Abstract]   [Full Text] [Related]  

  • 60. Divalproex sodium and quetiapine treatment of a pedophile with bipolar spectrum disorder.
    Wang SC; Kao YC; Liu YP
    J Neuropsychiatry Clin Neurosci; 2014; 26(3):E47-8. PubMed ID: 25093789
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.